Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis

American Society of Clinical Oncology (ASCO) - Tập 20 Số 5 - Trang 1248-1259 - 2002
Robert E. Bristow1, Rafael S. Tomacruz2, Deborah K. Armstrong2, Edward L. Trimble2, F J Montz2
1Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD 21287-1248, USA.
2From the Kelly Gynecologic Oncology Service, Johns Hopkins Medical Institutions, Baltimore, MD.

Tóm tắt

PURPOSE: To evaluate the relative effect of percent maximal cytoreductive surgery and other prognostic variables on survival among cohorts of patients with advanced-stage ovarian carcinoma treated with platinum-based chemotherapy.MATERIALS AND METHODS: Eighty-one cohorts of patients with stage III or IV ovarian carcinoma (6,885 patients) were identified from articles in MEDLINE (1989 through 1998). Linear regression models, with weighted correlation calculations, were used to assess the effects on log median survival time of the proportion of each cohort undergoing maximal cytoreduction, dose-intensity of the platinum compound administered, proportion of patients with stage IV disease, median age, and year of publication.RESULTS: There was a statistically significant positive correlation between percent maximal cytoreduction and log median survival time, and this correlation remained significant after controlling for all other variables (P < .001). Each 10% increase in maximal cytoreduction was associated with a 5.5% increase in median survival time. When actuarial survival was estimated, cohorts with ≤ 25% maximal cytoreduction had a mean weighted median survival time of 22.7 months, whereas cohorts with more than 75% maximal cytoreduction had a mean weighted median survival time of 33.9 months—an increase of 50%. The relationship between platinum dose-intensity and log median survival time was not statistically significant.CONCLUSION: During the platinum era, maximal cytoreduction was one of the most powerful determinants of cohort survival among patients with stage III or IV ovarian carcinoma. Consistent referral of patients with apparent advanced ovarian cancer to expert centers for primary surgery may be the best means currently available for improving overall survival.

Từ khóa


Tài liệu tham khảo

10.3322/canjclin.51.1.15

10.1016/0002-9378(92)91658-W

Venesmaa P: Epithelial ovarian cancer: Impact of surgery and chemotherapy on survival during 1977-1990. Obstet Gynecol 84: 8,1994-11,

10.3109/07853899509031943

10.3109/07853899509031944

10.1016/0090-8258(92)90107-T

10.1016/0090-8258(85)90141-6

Averette HE, Hoskins W, Nguyen HN, et al: National Survey of Ovarian Carcinoma: I. A patient care evaluation study of the American College of Surgeons. Cancer 71: 1629,1993-1638,

McGowan L: Patterns of care in carcinoma of the ovary. Cancer 71: 628,1993-633,

10.1002/1097-0142(19931215)72:12<3663::AID-CNCR2820721218>3.0.CO;2-S

Carney ME, Wiggins C, Ford C: A population-based study evaluating patterns of care for ovarian cancer: Who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 80: 278,2001 (abstr 10)

10.1093/jnci/85.21.1732

10.1200/JCO.1992.10.4.520

10.3109/02841868909111182

10.1159/000238673

10.1200/JCO.1989.7.2.223

10.1200/JCO.1989.7.4.457

10.1093/jnci/81.19.1464

10.1016/0090-8258(89)90636-7

Gurney H, Crowther D, Anderson H, et al: Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. Ann Oncol 1: 427,1990-433,

Fioretti P, Gadducci A, Del Bravo B, et al: The potential of primary cytoreductive surgery in patients with FIGO stages III and IV ovarian carcinoma. Eur J Gynaecol Oncol 11: 175,1990-179,

De Oliveira CF, Lacave AJ, Villani C, et al: Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). Eur J Gynaecol Oncol 11: 323,1990-330,

10.1016/0090-8258(90)90244-F

10.1200/JCO.1990.8.3.502

10.1200/JCO.1991.9.10.1793

10.1002/jso.2930480108

10.1093/annonc/2.suppl_2.131

10.1002/jso.2930460315

10.1200/JCO.1991.9.4.658

10.1016/0305-7372(91)90023-S

10.1016/0090-8258(92)90067-S

10.1038/bjc.1992.55

10.1200/JCO.1992.10.5.718

10.1016/0090-8258(92)90305-3

10.1046/j.1525-1438.1992.02060301.x

10.1046/j.1525-1438.1992.02050236.x

10.1159/000227155

10.1006/gyno.1993.1091

Alberts DS, Dahlberg S, Green SJ, et al: Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer: A Southwest Oncology Group study. Cancer 71: 618,1993-627,

Stoot J, Wils J, Geuns HV, et al: Chemotherapy consisting of cisplatin, epirubicin, and cyclophosphamide in advanced ovarian carcinoma. Cancer Invest 11: 1,1993-5,

10.1038/bjc.1993.502

10.1006/gyno.1993.1081

10.1006/gyno.1994.1082

10.1006/gyno.1994.1220

10.1200/JCO.1994.12.10.2066

10.1002/1097-0142(19940715)74:2<656::AID-CNCR2820740218>3.0.CO;2-6

10.1200/JCO.1995.13.7.1589

10.1016/0959-8049(95)00274-M

10.1006/gyno.1995.1241

10.1056/NEJM199612263352603

10.1200/JCO.1996.14.2.351

Van der Burg MEL, Van Lent M, Buyse M, et al: The role of intervention debulking surgery in advanced epithelial ovarian cancer: An EORTC Gynecological Cancer Cooperative Group study. Int J Gynecol Cancer 6: 30,1996-38, (suppl 1)

10.1016/0959-8049(95)00537-4

10.1046/j.1525-1438.1996.06010044.x

10.1046/j.1525-1438.1996.06050410.x

10.1002/(SICI)1097-0142(19960215)77:4<733::AID-CNCR20>3.0.CO;2-0

10.1006/gyno.1996.0334

10.1006/gyno.1997.4690

10.1046/j.1525-1438.7.s1.5.x

10.1200/JCO.1997.15.5.1938

10.1006/gyno.1997.4845

10.1097/00000421-199710000-00019

10.1006/gyno.1997.4913

10.1046/j.1525-1438.1998.97110.x

10.1006/gyno.1998.4955

10.1002/(SICI)1097-0142(19981101)83:9<1980::AID-CNCR14>3.0.CO;2-O

Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42: 101,1975-104,

10.1097/00006250-198606000-00007

10.1016/0090-8258(86)90001-6

10.1200/JCO.1988.6.6.983

10.1016/0090-8258(90)90042-J

10.1016/0090-8258(92)90100-W

Hacker NF, Berek JS, Lagasse LD, et al: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61: 413,1983-420,

10.1006/gyno.1994.1142

10.1006/gyno.2000.5926

10.1016/0277-5379(89)90208-3

Allen DG, Heintz APM, Touw FWMM: A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 16: 349,1995-355,

10.1006/gyno.1995.1273

10.1001/jama.1993.03500090055032

10.1016/0090-8258(91)90222-Q

10.1080/j.1600-0412.1998.770714.x

10.1006/gyno.2000.5923

10.1038/sj.bjc.6690376

10.1111/j.1471-0528.1999.tb08137.x

10.1006/gyno.1995.1027

10.1038/bjc.1994.307

10.1016/0002-9378(92)91554-N

Sigurdsson K, Alm P, Gullberg B: Prognostic factors in malignant epithelial ovarian tumors. Gynecol Oncol 15: 379,1983-380,

10.1016/0002-9378(79)90824-X

Michel G, De Iaco P, Castaigne D, et al: Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol 18: 9,1997-15,

10.1016/S0002-9378(96)70331-9

10.1016/0002-9378(92)91345-B

10.1002/1098-2388(200007/08)19:1<42::AID-SSU7>3.0.CO;2-M

Munnell EW: The changing prognosis and treatment in cancer of the ovary. Am J Obstet Gynecol 100: 790,1969-805,

10.1016/0090-8258(92)90110-5

10.1038/bjc.1994.440

10.1111/j.1471-0528.1997.tb11032.x

10.1200/JCO.2000.18.11.2327

10.1001/jama.280.20.1747

10.1097/00000658-199909000-00013

10.1378/chest.114.3.675

10.1056/NEJM199601043340101

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 20 Số 5

1248-1259

Thông tin tác giả